Colorectal Cancer
Oxaliplatin-based Chemotherapy - Prognostic impact of ETD or EOD in Stage III colon cancer patients
In patients treated with 6 months of #oxaliplatin-based chemotherapy for stage III #colon_cancer, the prognostic impact of early discontinuation of...
MMR-deficiency Prevalence among CRC patients
In a large study reported in the New England journal of medicine, 147 out of 5547 patients (2.7%) with rectal...
Colonoscopy benefits in CRC screening
Although #colonoscopy is widely used as a #screening test to detect colorectal cancer (#CRC), it is more invasive and resources...
TRIPLETE trial
In phase III TRIPLETE Study by GONO group, the intensification of the upfront chemotherapy backbone in combination with #panitumumab did...
FDA approval of bevacizumab biosimilar
On September 28th 2022, the FDA has approved Celltrion’s #bevacizumab biosimilar (bevacizumab-adcd) in six types of cancers which are: metastatic...
.png)